HolaSalud offers a digitally managed weight‑loss program that pairs FDA‑ and COFEPRIS‑approved GLP‑1 medications (such as Ozempic, Wegovy, and Mounjaro) with continuous telehealth supervision from board‑certified endocrinologists in Mexico. Users complete a brief health questionnaire, receive a personalized treatment plan—including medication, nutrition guidance, and lifestyle coaching—and track progress through a secure mobile app that provides ongoing expert support and medication delivery.
Funding
Funding not disclosed
Founders
Product
Problem
Many individuals with obesity struggle to achieve significant, sustained weight loss due to limited access to specialist care, safe pharmacologic options, and continuous medical support. Traditional diet and exercise programs often yield modest results and lack personalized medical oversight, leading to low adherence and suboptimal outcomes.
Solution
HolaSalud delivers a digitally managed weight‑loss program that combines FDA‑ and COFEPRIS‑approved GLP‑1 medications (such as Ozempic, Wegovy, and Mounjaro) with ongoing clinical supervision from Mexican endocrinology specialists. Users begin by completing a brief health questionnaire, after which a qualified physician determines whether lifestyle changes, GLP‑1 therapy, or a hybrid approach is appropriate. The service provides a secure mobile app for appointment scheduling, medication delivery coordination, and continuous monitoring of weight, metabolic markers, and side‑effects. Clinical teams review progress regularly and adjust treatment plans to ensure safety and effectiveness, aiming for up to 20 % body‑weight reduction. All patient data are encrypted and stored confidentially, complying with local health regulations.
Target Audience
Adults in Mexico with obesity or overweight conditions seeking medically supervised weight‑loss solutions, particularly those who prefer remote access to specialist care and prescription‑grade GLP‑1 therapies.
Features
- Integrated telehealth platform that connects patients with board‑certified endocrinologists for initial assessment and ongoing follow‑up
- Prescription and home delivery of GLP‑1 agonists (Ozempic, Wegovy, Mounjaro) approved by FDA and COFEPRIS
- Personalized treatment plans that combine medication, nutrition guidance, and lifestyle coaching
- Real‑time progress tracking within the app, including weight, BMI, and glucose metrics
- Secure, HIPAA‑like data handling ensuring patient confidentiality and compliance with Mexican health standards
- Continuous expert support via in‑app messaging and scheduled virtual consultations